Literature DB >> 25591157

Comparison of fecal elastase 1 for exocrine pancreatic insufficiency evaluation between ex-alcoholics and chronic pancreatitis patients.

Rejane Mattar1, Gustavo André Silva Lima1, Marianges Zadrozny Gouvêa da Costa1, Joyce M Kinoshita Silva-Etto1, Dulce Guarita1, Flair José Carrilho1.   

Abstract

CONTEXT: Fecal elastase is a noninvasive test for pancreatic insufficiency diagnosis.
OBJECTIVES: Evaluate the usefulness of fecal elastase 1 for the indication of exocrine pancreatic insufficiency among former alcohol addicts and patients with chronic pancreatitis.
METHODS: Forty-three patients with chronic pancreatitis and thirty-three asymptomatic former alcohol addicts entered the study. The levels of fecal elastase 1 were measured using a commercial kit. Pancreatic imaging findings were used to categorize the groups.
RESULTS: The levels of fecal elastase 1 were significantly lower in the patients than in the former alcohol addicts and in the group with tissue calcifications, duct alterations, or atrophy. With a cutoff level of 100 μg/g, the sensitivity of fecal elastase 1 in chronic pancreatitis was 46.51% and its specificity was 87.88% with a positive predictive value of 83.33% and a negative predictive value of 55.77%. When patients were stratified according to the severity of their pancreatitis, the sensitivity was 6.25% for mild pancreatitis and 70.37% for marked pancreatitis.
CONCLUSION: Low level of fecal elastase 1 was associated with marked rather than mild chronic pancreatitis; however, it may be useful to indicate pancreatic exocrine insufficiency in asymptomatic former alcohol addicts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25591157     DOI: 10.1590/S0004-28032014000400006

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  1 in total

1.  Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis.

Authors:  Rohini R Vanga; Aylin Tansel; Saad Sidiq; Hashem B El-Serag; Mohamed O Othman
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 11.382

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.